SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 5, 2012, Pages 1163-1166

  Reddy, Venkata M ^a   Dubuisson, Tia ^a   Einck, Leo ^a   Wallis, Robert S ^b   Jakubiec, Wesley ^c   Ladukto, Lynn ^c   Campbell, Sheldon ^c   Nacy, Carol A ^a  

^a SEQUELLA INC   (United States)

^b PFIZER INC   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Intracellular activity; Rate of killing; Whole blood bactericidal activity

Indexed keywords

N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; OXAZOLIDINONE DERIVATIVE; SUTEZOLID;

ANIMAL CELL; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BLOOD CULTURE; DRUG EFFICACY; IN VITRO STUDY; MACROPHAGE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; TUBERCULOSIS;

ADAMANTANE; ANIMALS; ANTITUBERCULAR AGENTS; CELL LINE; DRUG INTERACTIONS; ETHYLENEDIAMINES; MACROPHAGES; MICE; MICROBIAL VIABILITY; MYCOBACTERIUM TUBERCULOSIS; OXAZOLIDINONES;

EID: 84859569460     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr589     Document Type: Article

References (10)

1. Protopopova M, Hanrahan C, Nikonenko B et al. Identification of a new antitubercular drug candidate SQ109 from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 2005; 56: 968-74.
2. Eustice DC, Feldman GM, Zajac I et al. Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis. Antimicrob Agents Chemother 1988; 32: 1218-22.
3. Williams KN, Stover CK, Zhu T et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 2009; 53: 1314-9.
4. Reddy VM, Einck L, Andries K et al. In vitro interactions between new anti-tubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother 2010; 54: 2840-6.
5. Bogatcheva E, Dubuisson T, Protopopova M et al. Chemical modification of capuramycins to enhance antibacterial activity. J Antimicrob Chemother 2011; 66: 578-87.
6. Wallis RS, Vinhas SA, Johnson JL et al. Whole blood bactericidal activity during treatment of pulmonary tuberculosis. J Infect Dis 2003; 187: 270-8.
7. Wallis RS, JakubiecW, Kumar V et al. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob Agents Chemother 2011; 55: 567-74.
8. Alffenaar JWC, van der Lan T, Simons S et al. Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivative of linezolid, PNU-100480. Antimicrob Agents Chemother 2011; 55: 1287-9.
9. Dietze R, Hadad DJ, McGhee B et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 2008; 178: 1180-5.
10. Nikonenko BV, Protopopova M, Samala R et al. Drug therapy of experimental tuberculosis (TB): improved outcome of combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob Agents Chemother 2007; 51: 1563-5.